Core Insights - The brain-computer interface (BCI) sector is experiencing a significant increase in investment and financing activities, with notable funding rounds completed by companies like Shanghai Brain Rhythm Technology and Guangdong Daoshi Technology [1][4] - The technology is advancing from conceptual applications to real-world uses, spanning various fields such as medical rehabilitation, treatment of neurological diseases, cognitive enhancement, and human-machine collaboration [2] - Government policies are actively promoting the BCI industry, with initiatives aimed at creating industrial clusters, establishing key laboratories, and facilitating clinical applications [3] Investment Trends - Investment enthusiasm in the BCI sector is on the rise, with a notable increase in financing activities in the first half of the year, surpassing the total number from the previous year [4] - Companies like Beijing Zhiran Medical Technology have successfully raised significant funds, indicating market confidence in the potential of invasive BCI technologies [5] Technological Advancements - BCI technology is breaking traditional interaction methods, allowing for direct interpretation of neural signals and seamless conversion from "thought" to "command," which enhances its applicability across various domains [2] - Key technological breakthroughs, such as flexible electrodes and wireless power supply, are expected to facilitate multi-scenario applications in healthcare, consumer electronics, and industrial manufacturing [5] Policy Support - Various regions in China, including Beijing and Shanghai, have launched specific action plans to support the BCI industry, aiming for high-quality development and comprehensive clinical application by 2030 [3] - The establishment of industry standards and inclusion of BCI surgeries in medical insurance coverage are steps towards creating a complete commercialization loop for BCI technologies [3]

证券代码：300409 证券简称：道氏技术 公告编号：2025-096 广东道氏技术股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别风险提示： 广东道氏技术股份有限公司（以下简称"公司"）及其控股子公司对外担保 总额超过公司最近一期经审计净资产100%，前述担保均为公司合并范围内的担 保，担保风险可控，敬请投资者充分关注担保风险。 一、担保情况概述 公司于2025年4月22日召开第六届董事会2025年第7次会议、第六届监事会 2025年第5次会议，于2025年5月14日召开2024年年度股东大会，分别审议通过 了《关于2025年度公司及子公司向银行申请综合授信额度及为子公司提供担保 的议案》，同意公司为子公司提供合计不超过780,000.00万元担保额度，额度 有效期为自2024年年度股东大会审议通过之日起12个月。其中为芜湖佳纳能源 科技有限公司（以下简称"芜湖佳纳"）及其子公司提供不超过530,000.00万元的 担保额度；为佛山市格瑞芬新能源有限公司（以下简称"佛山格瑞芬"）及其子 公司提供不超过100, ...

Group 1 - The core viewpoint of the article is that Daoshi Technology's subsidiary, Hong Kong Jiana, has signed a Pre-B round preferred stock subscription agreement with Brain Family Inc., a leading brain-computer interface technology company, investing $30 million to acquire minority shareholder rights [1] - Brain Family Inc. has over 460 authorized patents and its core products have received multiple international certifications, including FDA and CE, indicating strong R&D capabilities and commercial applications in high-value fields such as medical rehabilitation, educational technology, consumer health, and human-computer interaction [1] - The investment aims to leverage opportunities in the AI era, enhancing the company's "AI + materials" strategy and improving its core competitiveness through collaboration with Brain Family Inc. in the application of carbon materials in areas like electronic skin [1] Group 2 - The preferred shares acquired by Hong Kong Jiana will have superior rights in liquidation, voting, and repurchase compared to common shares, and can be converted to common shares at a 1:1 ratio [1] - The pricing of the subscription was determined based on the industry characteristics, R&D strength, future potential of Brain Family Inc., and valuations from other investors in the Pre-B round [1]

Core Viewpoint - Guangdong Daoshi Technology Co., Ltd. announced its subsidiary Hong Kong Jian Na Limited plans to invest $30 million (approximately 213 million RMB) to acquire minority equity in Qiangnao Technology's Pre-B round preferred shares [1][4]. Company Overview - Qiangnao Technology, founded in February 2015 by Han Bicheng, focuses on the development of non-invasive brain-computer interface technology, which is safer and has a broader application range compared to invasive methods [3]. - The company relocated its headquarters to Hangzhou in 2018 and is part of a group of innovative tech firms known as the "Hangzhou Six Little Dragons" [3]. - Qiangnao Technology has launched several products, including smart bionic limbs and brain-machine intelligent sleep devices, indicating a shift from laboratory research to commercial application [3]. Investment Details - Daoshi Technology's investment in Qiangnao Technology aims to leverage the latter's experience in applying brain-computer interface technology in medical rehabilitation, education, and human-computer interaction, enhancing Daoshi's "AI + new materials" strategy [7]. - Qiangnao Technology is currently in the Pre-B round stage and has been rumored to be negotiating a pre-IPO financing of approximately $100 million at a valuation exceeding $1.3 billion, potentially paving the way for an IPO in Hong Kong or mainland China [5][4]. Financial Performance - Daoshi Technology reported a significant reduction in R&D expenses, down 41.39% year-on-year to 88.68 million RMB, attributed to decreased direct material inputs and personnel costs [9]. - The company’s revenue for the reporting period was approximately 3.65 billion RMB, reflecting an 11.64% decrease compared to the previous year [9]. Industry Context - The brain-computer interface industry, where Qiangnao Technology operates, is considered an emerging sector, with profitability expected to be achieved only after 2024 [10]. - Qiangnao Technology has raised over $1 billion in total funding since its inception, with a current valuation potentially reaching $5 billion [10].

Summary of the Conference Call for Dow's Technology Company and Industry Overview - **Company**: Dow's Technology - **Industry**: AI and Materials Science, specifically focusing on brain-machine interface technology and advanced materials for robotics and sensors [2][3] Core Points and Arguments - **Investment in Long Brain Technology**: Dow's Technology invested $30 million in Long Brain Technology, a leader in non-invasive brain-machine interface technology, founded by Dr. Han Bicheng from Harvard University [4] - **Strategic Goals**: The investment aims to enhance product development efficiency and iteration speed through AI capabilities, aligning with Dow's strategy to become a platform company integrating AI with materials [4] - **Role of New Peison**: New Peison is crucial in Dow's AI strategy, focusing on discovering new materials and enhancing existing ones, particularly in humanoid and special robots, and sensor materials [5] - **AI Chip Development**: New Peison specializes in computing chips, addressing complex AI problems that traditional methods struggle with, and has received recognition from experts in the field [6] - **Artificial Neural Networks**: These networks excel in solving complex problems that cannot be described by equations, such as language models and image recognition, primarily relying on GPU technology [7] Breakthroughs and Innovations - **Advancements in Computing**: New Peison achieved significant breakthroughs in addressing the "curse of dimensionality," improving speed and reducing power consumption in molecular dynamics and density functional theory calculations [8] - **APU Chip Applications**: The APU chip simulates the Schrödinger equation, applicable in various fields of materials science, including military, chemical, lithium battery, photovoltaic, semiconductor, and cosmetics [9][10] - **Future Development Plans**: New Peison plans to expand its technology applications to larger-scale problems, such as weather simulation and vehicle aerodynamics, by developing the EPU chip for high-speed, low-power calculations [11] Additional Important Insights - **Successful Transition**: Dow's Technology transitioned from a focus on ceramic ink materials to the renewable energy sector in 2018, leveraging AI opportunities for larger-scale development [12] - **Collaborative Strategy**: The collaboration with Long Brain Technology and other companies is part of a unified strategy of "AI + materials + applications," aiming for breakthroughs in new material development [5]

Group 1 - The core point of the article is that Dao's Technology announced the holding of its third extraordinary general meeting of shareholders for 2025 on September 3, 2025, to review and approve the proposal regarding the change of part of the fundraising purposes [2] Group 2 - The meeting was convened to discuss the adjustment of the use of raised funds, indicating a strategic shift in the company's financial management [2]

证券代码：300409 证券简称：道氏技术 公告编号：2025-095 广东道氏技术股份有限公司 2025年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 1、会议召集人：广东道氏技术股份有限公司（以下简称"公司"）董事会 特别提示： 1、本次股东大会没有出现否决议案的情形。 2、本次股东大会没有涉及变更前次股东大会已通过的决议。 3、本次股东大会采取现场投票和网络投票相结合的方式召开。 一、会议召开情况 2、会议召开日期与时间： 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 3 日 9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系 统投票的具体时间为 2025 年 9 月 3 日 9:15 至 15:00 期间的任意时间。 3、会议召开地点：广东省佛山市禅城区南庄镇怡水三路 1 号 1 座佛山市道 氏科技有限公司 5 楼会议室。 （1）现场会议召开时间：2025 年 9 月 3 日（星期三）14:00 （2）网络投票时间：2025 年 9 月 3 日 ...

北京市中伦（深圳）律师事务所 关于广东道氏技术股份有限公司 2025 年第三次临时股东大会的 法律意见书 北京市中伦（深圳）律师事务所 关于广东道氏技术股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：广东道氏技术股份有限公司 二〇二五年九月 | 四、结论意见 4 | | --- | 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》以及中国证券监督管理委员会（以下简称"中国证监会"）发布 的《上市公司股东会规则》的规定，北京市中伦（深圳）律师事务所（以下简称 "本所"）接受广东道氏技术股份有限公司（以下简称"公司"）的委托，指派 本所律师列席公司 2025 年第三次临时股东大会（以下简称"本次股东大会"）， 本所指派的律师通过现场和实时视频方式对本次股东大会的相关事项进行见证 并出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的包括但不限于如下相关文 件： 1. 公司现行有效的公司章程； 2. 公司于 2025 年 8 月 19 日刊登于巨潮资讯网（www.cninfo.com.cn）的第 六届董事会 2025 年第 12 次会议决议； 3. 公司 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - As of September 3, the graphite electrode concept increased by 0.02%, ranking 6th among concept sectors, with 7 stocks rising, including Ningxin New Materials, Dow Technology, and Zhongke Electric, which rose by 10.79%, 9.74%, and 6.21% respectively [1] - The leading stocks in the graphite electrode sector by net inflow of main funds include Zhongke Electric with a net inflow of 218 million yuan, followed by Dow Technology, Suotong Development, and Putailai with net inflows of 179 million yuan, 53 million yuan, and 16 million yuan respectively [2][3] - The main fund inflow ratios for Huajin Co., Zhongke Electric, and Suotong Development were 9.19%, 7.63%, and 6.26% respectively, indicating strong interest in these stocks [3] Group 2 - The stocks with the largest declines in the graphite electrode sector include Better Ray, Longjiang Transportation, and Baotailong, which fell by 3.83%, 3.39%, and 2.46% respectively [1] - The overall market performance for the graphite electrode concept shows a mixed trend, with some stocks experiencing significant gains while others faced notable losses [2][4]